S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
Dems' climate, energy, tax bill clears initial Senate hurdle
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
Dems' climate, energy, tax bill clears initial Senate hurdle
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
Dems' climate, energy, tax bill clears initial Senate hurdle
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
Dems' climate, energy, tax bill clears initial Senate hurdle
NASDAQ:ARNA

Arena Pharmaceuticals - ARNA Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$99.99
$99.99
50-Day Range
$93.13
$99.99
52-Week Range
$45.50
$100.00
Volume
107 shs
Average Volume
1.56 million shs
Market Capitalization
$6.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$95.60

Arena Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
4.4% Downside
$95.60 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.78
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($8.32) to ($6.78) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.30 out of 5 stars

Medical Sector

1126th out of 1,283 stocks

Pharmaceutical Preparations Industry

538th out of 615 stocks

ARNA stock logo

About Arena Pharmaceuticals (NASDAQ:ARNA) Stock

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

Receive ARNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARNA Stock News Headlines

7 Biotech Stocks With Key Catalysts in March
Arena Pharmaceuticals GAAP EPS of -$2.54 misses by $0.31
SFO opens criminal probe into collapse of Arena Television
Expert Ratings For Arena Pharmaceuticals
See More Headlines

Receive ARNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARNA Company Calendar

Last Earnings
11/04/2021
Today
8/07/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ARNA
CUSIP
04004710
Employees
448
Year Founded
1977

Price Target and Rating

Average Stock Price Forecast
$95.60
High Stock Price Forecast
$105.00
Low Stock Price Forecast
$71.00
Forecasted Upside/Downside
-4.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
10 Analysts

Profitability

Net Income
$-616,430,000.00
Pretax Margin
-1,141,542.63%

Debt

Sales & Book Value

Annual Sales
$50,000.00
Price / Sales
123,305.67
Book Value
$10.94 per share

Miscellaneous

Free Float
60,173,000
Market Cap
$6.17 billion
Optionable
Optionable
Beta
0.55

Social Links


Key Executives














ARNA Stock - Frequently Asked Questions

Should I buy or sell Arena Pharmaceuticals stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. There are currently 10 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Arena Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARNA, but not buy additional shares or sell existing shares.
View analyst ratings for Arena Pharmaceuticals
or view top-rated stocks.

What is Arena Pharmaceuticals' stock price forecast for 2022?

10 brokerages have issued twelve-month price targets for Arena Pharmaceuticals' shares. Their ARNA stock forecasts range from $71.00 to $105.00. On average, they predict Arena Pharmaceuticals' share price to reach $95.60 in the next year. This suggests that the stock has a possible downside of 4.4%.
View analysts' price targets for Arena Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How were Arena Pharmaceuticals' earnings last quarter?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($3.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.53) by $0.68. During the same quarter in the prior year, the firm earned ($1.69) EPS.

When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?

Arena Pharmaceuticals shares reverse split on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What is Amit Munshi's approval rating as Arena Pharmaceuticals' CEO?

16 employees have rated Arena Pharmaceuticals CEO Amit Munshi on Glassdoor.com. Amit Munshi has an approval rating of 66% among Arena Pharmaceuticals' employees.

What other stocks do shareholders of Arena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Cytokinetics (CYTK), Micron Technology (MU), NVIDIA (NVDA), Novavax (NVAX), Alibaba Group (BABA), GW Pharmaceuticals (GWPH) and AT&T (T).

What is Arena Pharmaceuticals' stock symbol?

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

What is Arena Pharmaceuticals' stock price today?

One share of ARNA stock can currently be purchased for approximately $99.99.

How much money does Arena Pharmaceuticals make?

Arena Pharmaceuticals (NASDAQ:ARNA) has a market capitalization of $6.17 billion and generates $50,000.00 in revenue each year. The biopharmaceutical company earns $-616,430,000.00 in net income (profit) each year or ($10.13) on an earnings per share basis.

How many employees does Arena Pharmaceuticals have?

Arena Pharmaceuticals employs 448 workers across the globe.

When was Arena Pharmaceuticals founded?

Arena Pharmaceuticals was founded in 1977.

How can I contact Arena Pharmaceuticals?

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The official website for Arena Pharmaceuticals is www.arenapharm.com. The biopharmaceutical company can be reached via phone at (858) 453-7200, via email at ir@arenapharm.com, or via fax at 858-453-7210.

This page (NASDAQ:ARNA) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.